Seaweed extract composition for retardation of cardiovascular disorders and preservation of healthy cardiovascular function

Abstract

The invention of comprises of a method and composition for retardation of cardiovascular disorder in a mammal comprising the step of administering to a mammal an amount of seaweed extract in effective doses. The invention also comprises a composition and method for preserving cardiovascular health in a mammal comprising the step of administering to a mammal an amount of seaweed extract in effective doses. The seaweed is selected from the group consisting of brown algae, red algae and green algae, wherein the seaweed extract contains a polysaccharide. Optionally, the polysaccharide is Rhamnose, in approximately 70 mole %. The seaweed extract optionally also contains approximately 6.5 mole % Xylose. Optionally, Rhamnose and Xylose are present in the seaweed extract in amounts in a ratio of approximately 11 Rhamnose to 1 Xylose. Optionally, the seaweed extract is mixed with food stuffs such as cereals, bread, drinks, health bars, juices, concentrates, canned food, ice cream, water, staple goods such as wheat, corn, barley, and oat in any form, or taste maskers such as sugar or ascorbic acid.

The following is claimed:  
     
         1 . A method for retardation of cardiovascular disorder in a mammal comprising the step of administering to a mammal an amount of seaweed extract in effective doses.  
     
     
         2 . The method of  claim 1  wherein the seaweed is selected from the group consisting of brown algae, red algae and green algae.  
     
     
         3 . The method of  claim 1  wherein the seaweed extract contains a polysaccharide.  
     
     
         4 . The method of  claim 3  wherein the polysaccharide is selected from the group consisting of; Rhamnose, Xylose, Galactose, and Mannose, either individually or a combination thereof.  
     
     
         5 . The method of  claim 1  wherein the seaweed extract contains between approximately 63 mole % to 78 mole % Rhamnose.  
     
     
         6 . The method of  claim 1  wherein the seaweed extract contains between approximately 6.5 mole % to 9.2 mole % Xylose.  
     
     
         7 . The method of  claim 1  wherein Rhamnose and Xylose are present in the seaweed extract in amounts between a ratio of approximately 12 Rhamnose to 1 Xylose and approximately 8 Rhamnose to 1 Xylose.  
     
     
         8 . The method of  claim 2  wherein the brown algae is selected from the group consisting of  Fucus vesiculosus, Fucus Evanescens, Laminaria brasiliensis,  or  Ascophylum nodosum.    
     
     
         9 . The method of  claim 2  wherein the green algae is selected from the group consisting of  Monostroma nitidium, Monostroma zosteticola, Monostroma angicava, Monostroma lattissimum, Monostroma pulchrum, Monostroma fusem, Monostroma grevillei, Entoromorpha compressa, Ulva arasakii, Ulva Pertussa, Cladophora denna, Cladophora rugulosa, Chaecomorpha spiralis, Chaecomorpha crassa, Spongomorpha duriuscula, Codium fragile, Codium divaricaium Codium latum,  or  Caulerpa okamarai.    
     
     
         10 . The method of  claim 1  wherein the dose of seaweed extract is administered to reduce the risk of formation of hard clots in mammalian blood vessels.  
     
     
         11 . The method of  claim 1  wherein the dose of seaweed extract is administered to the mammal to reduce the risk of heart attack.  
     
     
         12 . The method of  claim 1  wherein the cardiovascular disorder is caused by endothelial dysfunction.  
     
     
         13 . The method of  claim 1  wherein the cardiovascular disorder is selected from the group consisting of atherosclerosis, arteriosclerosis, congestive heart failure, arterial stenosis, cardiac cell hypertrophy, endothelial cell surface thrombogenecity, myocardial infarction, cerebrovascular ischemia, peripheral vascular ischemia, angina pectoris, and hypertension.  
     
     
         14 . The method of  claim 1  further comprising the co-administration of a nitrogen donor together with the seaweed extract.  
     
     
         15 . The method of  claim 14  wherein the nitrogen donor is selected from the group consisting of L-Arginine and Lysine.  
     
     
         16 . The method of  claim 1  wherein the seaweed extract is administered orally.  
     
     
         17 . The method of  claim 1 , wherein the seaweed extract is mixed with food stuffs; wherein the food stuffs is selected from the group consisting of cereals, bread, drinks, health bars, juices, concentrates, canned food, ice cream, water, staple goods such as wheat, corn, barley, and oat in any form, or taste maskers such as sugar or ascorbic acid.  
     
     
         18 . The method of  claim 1  wherein a daily dose of seaweed extract is equivalent to between approximately 2,000IU and 200,000IU of heparin activity.  
     
     
         19 . The method of  claim 1  wherein a daily dose of seaweed extract is equivalent to between approximately 5,000IU and 20,000IU of heparin activity.  
     
     
         20 . The method of  claim 1  wherein a daily dose of seaweed extract is equivalent to between approximately 8,000IU and 12,000IU of heparin activity.  
     
     
         21 . The method of  claim 1  wherein a daily dose of seaweed extract is approximately 7.5 mg/kg.  
     
     
         22 . The method of  claim 1  wherein the dose of seaweed extract is repeated.  
     
     
         23 . The method of  claim 1  wherein the anticoagulation activity in the blood plasma of the mammal is not appreciably increased.  
     
     
         24 . A composition for retardation of cardiovascular disorder in patients comprising: an amount of seaweed extract and a nitrogen donor in effective amounts.  
     
     
         25 . The composition of  claim 24  wherein the seaweed is selected from the group of brown algae, red algae and green algae.  
     
     
         26 . The composition of  claim 25  wherein the brown algae is selected from the group consisting of  Fucus vesiculosus, Fucus Evanescens Laminaria brasiliensis,  or  Ascophylum nodosum.    
     
     
         27 . The composition of  claim 25  wherein the green algae is selected from the group consisting of  Monostroma nitidium, Monostroma zosteticola, Monostroma angicava, Monostroma lattissimum, Monostroma pulchrum, Monostroma fusem, Monostroma grevillei, Entoromorpha compressa, Ulva arasakii, Ulva Pertussa, Cladophora denna, Cladophora rugulosa, Chaecomorpha spiralis, Chaecomorpha crassa, Spongomorpha duriuscula, Codium fragile, Codium divaricaium Codium latum,  or  Caulerpa okamarai.    
     
     
         28 . The composition of  claim 24  wherein the seaweed extract contains a polysaccharide.  
     
     
         29 . The composition of  claim 28  wherein the polysaccharide is selected from the group consisting of; Rhamnose, Xylose, Galactose, and Mannose, either individually or a combination thereof.  
     
     
         30 . The composition of  claim 24  wherein the seaweed extract contains between approximately 63 mole % to 78 mole % Rhamnose.  
     
     
         31 . The composition of  claim 24  wherein the seaweed extract contains between approximately 6.5 mole % to 9.2 mole % Xylose.  
     
     
         32 . The composition of  claim 29  wherein Rhamnose and Xylose are present in the seaweed extract in amounts between a ratio of approximately 12 Rhamnose to 1 Xylose and approximately 8 Rhamnose to 1 Xylose.  
     
     
         33 . The composition of  claim 24  wherein the seaweed extract is mixed with food stuffs.  
     
     
         34 . The composition of  claim 33 , wherein the food stuffs is selected from the group consisting of cereals, bread, drinks, health bars, juices, concentrates, canned food, ice cream, water, staple goods such as wheat, corn, barley, and oat in any form, or taste maskers such as sugar or ascorbic acid.  
     
     
         35 . The composition of  claim 24  wherein a daily amount of administered seaweed extract is equivalent to between approximately 2,000IU and 200,000IU of heparin activity.  
     
     
         36 . The composition of  claim 24  wherein a daily amount of administered seaweed extract is equivalent to between approximately 5,000IU and 20,000IU of heparin activity.  
     
     
         37 . The composition of  claim 24  wherein a daily amount of administered seaweed extract is equivalent to between approximately 8,000IU and 12,000IU of heparin activity.  
     
     
         38 . The composition of  claim 24  wherein the nitrogen donor is selected from the group consisting of L-Arginine and Lysine.  
     
     
         39 . The composition of  claim 24  wherein the seaweed is substituted for by its functional analogs, wherein the functional analogs are polysaccharides produced synthetically or derived from plant sources, such as algae, and treat cardiovascular disorder.  
     
     
         40 . A method for preserving cardiovascular health in a mammal comprising the step of administering to a mammal an amount of seaweed extract in effective doses.  
     
     
         41 . The method of  claim 40  wherein the seaweed is selected from the group of brown algae, red algae and green algae.  
     
     
         42 . The method of  claim 40  wherein the seaweed extract comprises a polysaccharide.  
     
     
         43 . The method of  claim 42  wherein the polysaccharide is selected from the group consisting of; Rhamnose, Xylose, Galactose, and Mannose, either individually or a combination thereof.  
     
     
         44 . The method of  claim 40  wherein the seaweed extract contains between approximately 63 mole % to 78 mole % Rhamnose.  
     
     
         45 . The method of  claim 40  wherein the seaweed extract contains between approximately 6.5 mole % to 9.2 mole % Xylose.  
     
     
         46 . The method of  claim 40  wherein Rhamnose and Xylose are present in the seaweed extract in amounts between a ratio of approximately 12 Rhamnose to 1 Xylose and approximately 8 Rhamnose to 1 Xylose.  
     
     
         47 . The method of  claim 41  wherein the brown algae is selected from the group consisting of  Fucus vesiculosus, Fucus Evanescens Laminaria brasiliensis,  or  Ascophylum nodosum.    
     
     
         48 . The method of  claim 41  wherein the green algae is selected from the group consisting of  Monostroma nitidium, Monostroma zosteticola, Monostroma angicava, Monostroma lattissimum, Monostroma pulchrum, Monostroma fusem, Monostroma grevillei, Entoromorpha compressa, Ulva arasakii, Ulva Pertussa, Cladophora denna, Cladophora rugulosa, Chaecomorpha spiralis, Chaecomorpha crassa, Spongomorpha duriuscula, Codium fragile, Codium divaricaium Codium latum,  or  Caulerpa okamarai.    
     
     
         49 . The method of  claim 40  wherein the dose of seaweed extract is administered to reduce the risk of formation of clots in mammalian blood vessels.  
     
     
         50 . The method of  claim 40  wherein the dose of seaweed extract is administered to the mammal to reduce the risk of heart attack.  
     
     
         51 . The method of  claim 40  wherein preservation of cardiovascular health comprises of reducing the risk of development of atherosclerosis, arteriosclerosis, congestive heart failure, arterial stenosis, cardiac cell hypertrophy, endothelial cell surface thrombogenecity, myocardial infarction, cerebrovascular ischemia, peripheral vascular ischemia, angina pectoris, hypertension.  
     
     
         52 . The method of  claim 40  further comprising the co-administration of a nitrogen donor together with the seaweed extract.  
     
     
         53 . The method of  claim 52  wherein the nitrogen donor is selected from the group consisting of L-Arginine and Lysine.  
     
     
         54 . The method of  claim 40  wherein the seaweed extract is administered orally.  
     
     
         55 . The method of  claim 52 , wherein the seaweed extract is administered mixed with food stuffs, wherein the food stuffs is selected from the group consisting of cereals, bread, drinks, health bars, juices, concentrates, canned food, ice cream, water, staple goods such as wheat, corn, barley, and oat in any form, or taste maskers such as sugar or ascorbic acid.  
     
     
         56 . The method of  claim 40  wherein a daily dose of seaweed extract is equivalent to between approximately 2,000IU and 200,000IU of heparin activity.  
     
     
         57 . The method of  claim 40  wherein a daily dose of seaweed extract is equivalent to between approximately 5,000IU and 20,000IU of heparin activity.  
     
     
         58 . The method of  claim 40  wherein a daily dose of seaweed extract is equivalent to between approximately 8,000IU and 12,000IU of heparin activity.  
     
     
         59 . The method of  claim 40  wherein a daily dose of seaweed extract is approximately 7.5 mg/kg.  
     
     
         60 . The method of  claim 40  wherein the dose of seaweed extract is repeated.  
     
     
         61 . The method of  claim 40  wherein the anticoagulation activity in the blood plasma of the mammal is not appreciably increased.  
     
     
         62 . A composition for preserving cardiovascular health in a mammal comprising; an amount of seaweed extract and a nitrogen donor in effective amounts.  
     
     
         63 . The composition of  claim 62  wherein the seaweed is selected from the group of brown algae, red algae and green algae.  
     
     
         64 . The composition of  claim 63  wherein the brown algae is selected from the group consisting of  Fucus vesiculosus, Fucus Evanescens, Laminaria brasiliensis,  or  Ascophylum nodosum.    
     
     
         65 . The composition of  claim 63  wherein the green algae is selected from the group consisting of  Monostroma nitidium, Monostroma zosteticola, Monostroma angicava, Monostroma lattissimum, Monostroma pulchrum, Monostroma fusem, Monostroma grevillei, Entoromorpha compressa, Ulva arasakii, Ulva Pertussa, Cladophora denna, Cladophora rugulosa, Chaecomorpha spiralis, Chaecomorpha crassa, Spongomorpha duriuscula, Codium fragile, Codium divaricaium Codium latum,  or  Caulerpa okamarai.    
     
     
         66 . The composition of  claim 62  wherein the seaweed extract contains a polysaccharide.  
     
     
         67 . The composition of  claim 66  wherein the polysaccharide is selected from the group consisting of; Rhamnose, Xylose, Galactose, and Mannose, either individually or a combination thereof.  
     
     
         68 . The composition of  claim 62  wherein the seaweed extract contains between approximately 63 mole % to 78 mole % Rhamnose.  
     
     
         69 . The composition of  claim 62  wherein the seaweed extract contains between approximately 6.5 mole % to 9.2 mole % Xylose.  
     
     
         70 . The composition of  claim 67  wherein Rhamnose and Xylose are present in the seaweed extract in amounts between a ratio of approximately 12 Rhamnose to 1 Xylose and approximately 8 Rhamnose to 1 Xylose.  
     
     
         71 . The composition of  claim 62  wherein the seaweed extract is mixed with food stuffs.  
     
     
         72 . The composition of  claim 71 , wherein the food stuffs is selected from the group consisting of cereals, bread, drinks, health bars, juices, concentrates, canned food, ice cream, water, staple goods such as wheat, corn, barley, and oat in any form, or taste maskers such as sugar or ascorbic acid.  
     
     
         73 . The composition of  claim 62  wherein a daily amount of administered seaweed extract is equivalent to between approximately 2,000IU and 200,000IU of heparin activity.  
     
     
         74 . The composition of  claim 62  wherein a daily amount of administered seaweed extract is equivalent to between approximately 5,000IU and 20,000IU of heparin activity.  
     
     
         75 . The composition of  claim 62  wherein a daily amount of administered seaweed extract is equivalent to between approximately 8,000IU and 12,000IU of heparin activity.  
     
     
         76 . The composition of  claim 62  wherein the nitrogen donor is selected from the group consisting of L-Arginine and Lysine.  
     
     
         77 . The composition of  claim 62  wherein the seaweed is substituted for by its functional analogs, wherein the functional analogs are polysaccharides produced synthetically or derived from plant sources, such as algae, and treat cardiovascular disorder.